Cetera Investment Advisers
FBLG icon

Cetera Investment Advisers’s FibroBiologics FBLG Stock Holding History

Cetera Investment Advisers’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-900
Closed -$4.05K – 4992
2025
Q4 		$4.05K Hold
900
– – ﹤0.01% 4636
2025
Q3 		$9.84K Sell
900
-50
-5% -$599 ﹤0.01% 4519
2025
Q2 		$11.8K Buy
950
+93
+11% +$1.68K ﹤0.01% 4046
2025
Q1 		$15.4K Buy
857
+202
+31% +$5.77K ﹤0.01% 3927
2024
Q4 		$26.2K Sell
655
-53
-7% -$2.85K ﹤0.01% 3695
2024
Q3 		$43.8K Buy
+708
New +$47.1K ﹤0.01% 3608

Other funds holding FBLG

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FEG
Fund Evaluation Group Cincinnati, Ohio $3.25B AUM 14.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

Cetera Investment Advisers's FBLG Position: Q1 2026 in Review

Cetera Investment Advisers sold out of FibroBiologics (FBLG) in Q1 2026, closing a stake of 900 shares — an estimated $4.05K sold.

Cetera Investment Advisers first reported a position in FBLG in Q3 2024 and held it in 6 quarters. The position peaked at $43.8K in Q3 2024. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

  • Cetera Investment Advisers reported no remaining FibroBiologics position as of Q1 2026 after selling out during the quarter.
  • Cetera Investment Advisers sold 900 FibroBiologics shares in Q1 2026, an estimated $4.05K.
  • Cetera Investment Advisers first reported a position in FibroBiologics in Q3 2024 and held it in 6 quarters.
  • Cetera Investment Advisers's FibroBiologics position peaked at $43.8K in Q3 2024.
  • 17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.